替米沙坦与代谢综合征.pptx
《替米沙坦与代谢综合征.pptx》由会员分享,可在线阅读,更多相关《替米沙坦与代谢综合征.pptx(69页珍藏版)》请在咨信网上搜索。
1、 Willa Hsueh,M.D.Professor of MedicineProfessor of MedicineChief,Division of Endocrinology,Diabetes,and Hypertension Chief,Division of Endocrinology,Diabetes,and Hypertension UCLA David Geffen School of Medicine UCLA David Geffen School of Medicine Los Angeles,CaliforniaLos Angeles,CaliforniaCardiov
2、ascular Risk Continuum:Implications of Insulin Resistance and DiabetesDiabetes is a vascular disease:Angiotensin II has been implicated in both the development of diabetes and its complicationsDiabetes Insulin-mediated glucose uptake Skeletal muscle Skeletal muscle Adipose Adipose FFA Inflammatory A
3、dipokinesLiver Liver Glucose productionPancreas Pancreas Insulin production Atherosclerosis Atherosclerosis CAD,Stroke,Peripheral vascular diseaseDiabetic Diabetic Diabetic NephropathyNephropathyNephropathy Albumin excretionDiabetic Diabetic RetinopathyRetinopathy VEGF neovascularizationDiastolic dy
4、sfunction,interstitial fibrosis heart failureCardiomyopathyCardiomyopathy IL6PAI-1TNF adiponectinleptinInsulin sensitivityinsulin resistanceVascular inflammationendothelial dysfunctionangiotensinogenFFAAdipokines Mediate Insulin Resistance and InflammationProgression of Atherosclerosis in Insulin Re
5、sistanceEndothelial Dysfunction TG,HDL-C sd LDL-C Hypertension Uric Acid PAI-1 Inflammation Thrombosis Oxidation Atherosclerosis Atherosclerosis Unstable plaque Inflammation,Fibrosis Cap Thrombosis and Rupture Event Hyperinsulinemia Metabolic Syndrome Impaired Glucose Tolerane Type 2 Diabetes Hsueh
6、WA,Law R.AJC,2003 Insulin ResistanceFor individuals born in 2000:Males 32.8%Females 38.5%Estimated loss of life expectancy if diagnosed at age 40:Males 11.6 years Females 14.3 years Narayan JAMA 2003 Lifetime Risk for Diabetes in the US 13NH3 13NH3 13NH3 Dipyridamole(0.56 mg/kg)135RestQuinones et al
7、 Ann Intern Med.,2004;140:700-8 Noninvasive Measurements of Noninvasive Measurements of Myocardial Blood Flow:Positron Emission TomographyMyocardial Blood Flow:Positron Emission Tomography025457090115CPTDIPApproaches that Improve Coronary Vasomotor Function in Insulin Resistance:Insulin sensitizers:
8、TZDs,PPAR ligands AT1 receptor blockers:ARBs Glucose control in type 2 diabetes:Metformin VALUE(Valsartan Antihypertensive Long-Term Use Evaluation):23%less new onset diabetes with valsartan compared to amlodipine in patients with hypertension HOPE(Heart Outcomes Prevention Evaluation):32%less new o
9、nset diabetes with ramipril compared to placebo in high cardiovascular risk patients LIFE(Losartan Intervention for Endpoint Reduction in Hypertension):25%less new onset diabetes with losartan compared to atenolol in patients with hypertension and left ventricular hypertrophyCHARM(Candesartan in Hea
10、rt Failure:Assessment of Reduction in Mortality and Morbidity):40%less new onset diabetes with candesartan in patients with heart failureInhibition of the Renin-angiotensin System Prevents Diabetes:Mechanisms by Which ACEIs and ARBs Prevent Diabetes:Improve endothelial function:Up to 40%of insulin-m
11、ediated glucose uptake may be endothelial dependent Allow fat cell differentiation Protect islet cells?Alter adipokine production?Alter liver glucose production Angiotensin IIAngiotensin IIinflammationinflammationoxidationoxidationthrombosisthrombosisvascular growth vascular growth and remodelingand
12、 remodelinghypertensionhypertensionPPAR Ligands AT1 Receptor Blockers reverse reverse cholesterol cholesterol transporttransportAngiotensin II Activates Multiple Mechanisms Promoting Tissue Injury that are Antagonized by PPAR LigandsNuclear Receptors Nuclear Receptors PPARsPPARsKidney proteinuria Pa
13、ncreas -cell protection Blood Vessels atherosclerosis blood pressureEye neovascularizationAdipocyte inflammatory factors antiinflammatory factorsglucose uptake in response to insulin,reverse metabolic syndromePPAR Impacts Multiple Aspects of DiabetesEffects of PPAR Ligands on Atherosclerosis inAngII
14、-Infused Male LDLR-/-MicePPAR Ligands Consistently Attenuates Albuminuria in Patients and Animal Models with Type 2 DiabetesTroglitazone ameliorates albuminuria in streptozotocin-induced diabetic rats.Fujii,M et al.Metabolism,1997 Effect of troglitazone on microalbuminuria in patients with incipient
15、 diabetic nephropathy.Imano,E et al.Diabetes Care,1998 Expression and function of peroxisome proliferator-activated receptor-y in mesangial cells.Nicholas et al Hypertension,2001 Rosiglitazone reduces urinary albumin excretion in type II diabetes.Bakris et al J Human Hypertension,2003Ligands PAI-1 e
16、xpression Growth TGF effects on ECM productionNicholas SB,et al Hypertension 37(Part 2):722-727,2001PPARPPAR Expressed on Mesangial Cell Expressed on Mesangial CellTRO Inhibits Capillary-Tube FormationControlTRO-treatedMurata et al.Invest Ophthalmol Vis Sci.41:2309-2317,2000Retinal Neovascularizatio
17、n in Control and TZD-treated Hypoxic MiceTelmisartanDoes it have dual activity to inhibit the AT1 receptor and activate PPAR?Kurtz TW,et al,Hypertension 43:993-1002,2004Schupp M.,et al,Circulation 109:2054-7,2004 ONTARGET:Telmisartan Ramipril in high risk patients CV endpoints,new onset type 2 diabe
18、tes,nephropathy,cognition Unger T.,Am J.Cardiol 91(suppl):28G-34G,2003 Center for Consumer Freedom Identification of New Treatment Strategies for Insulin Resistance,Metabolic Syndrome and Hypertension Theodore W Kurtz USA Hypertension:More Than Just High BP Metabolic Syndrome Insulin resistance,Dysl
19、ipidemia,&Increased BP Affects 15-25%of individuals in industrialized populations 2-4 fold risk in cardiovascular mortality 5-9 fold risk for developing type 2 diabetes*Not effectively treated by current antihypertensive drugs*Angiotensin II Receptor Blockers(ARBs)Hypertension Insulin Resistance Dys
20、lipidemia?H O O C N N N N O S N H O O N AII Receptor Blocker Telmisartan PPAR Ligand Pioglitazone PPAR A cellular receptor that is a A cellular receptor that is a provenproven therapeutic therapeutic target in the treatment of insulin resistance,target in the treatment of insulin resistance,diabetes
21、,and the metabolic syndromediabetes,and the metabolic syndrome Peroxisome proliferator activated receptor-gammaPeroxisome proliferator activated receptor-gamma PPAR Activators Approved for the Treatment of Type 2 Diabetes Fatty Acids/TriglyceridesInsulin Sensitivity HDL Actos(Lilly/Takeda)(Avandia-G
22、SK)Millions of Prescriptions Written2Losartan 46810121416Eprosartan Irbesartan Valsartan Candesartan Telmisartan Fold activation Olmesartan 5 micromolar Ability of Different ARBs To Activate PPAR (S.C.Benson et al.,Hypertension,43:993-1002,2004)Telmisartan is a Partial Agonist of PPAR (Schupp et al.
23、,Circulation,109:2054-2057,2004)Luciferase activity x-fold induction over vehicle treated cellsPioglitazone Telmisartan mol/LiterMechanism Whereby PPARMechanism Whereby PPAR Activators Activators Improve Insulin Resistance and the Metabolic Improve Insulin Resistance and the Metabolic SyndromeSyndro
24、me PPAR Activator Expression of Key Target Genes Receptor complex DBD PPAR DNA response elements CytoplasmNucleus RXR Ability of Telmisartan to Activate Key Anti-Diabetic Target Genes of PPAR Gene Encoding PEPCK Telmisartan 22.5 micromolar 3Val Irb 14Fold activaitonCan Olm Epro Exp(Benson et al.,Hyp
25、ertension,43:993-1002,2004)It is also a PPAR Activator-Telmisartan is Not Just an ARB-u Cellular differentiation assaysu Target gene expression assaysu Receptor transactivation assaysWhat is the clinical evidence that telmisartan can improve glucose and lipid metabolism as one would expect for a PPA
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 替米沙坦 代谢 综合征
1、咨信平台为文档C2C交易模式,即用户上传的文档直接被用户下载,收益归上传人(含作者)所有;本站仅是提供信息存储空间和展示预览,仅对用户上传内容的表现方式做保护处理,对上载内容不做任何修改或编辑。所展示的作品文档包括内容和图片全部来源于网络用户和作者上传投稿,我们不确定上传用户享有完全著作权,根据《信息网络传播权保护条例》,如果侵犯了您的版权、权益或隐私,请联系我们,核实后会尽快下架及时删除,并可随时和客服了解处理情况,尊重保护知识产权我们共同努力。
2、文档的总页数、文档格式和文档大小以系统显示为准(内容中显示的页数不一定正确),网站客服只以系统显示的页数、文件格式、文档大小作为仲裁依据,平台无法对文档的真实性、完整性、权威性、准确性、专业性及其观点立场做任何保证或承诺,下载前须认真查看,确认无误后再购买,务必慎重购买;若有违法违纪将进行移交司法处理,若涉侵权平台将进行基本处罚并下架。
3、本站所有内容均由用户上传,付费前请自行鉴别,如您付费,意味着您已接受本站规则且自行承担风险,本站不进行额外附加服务,虚拟产品一经售出概不退款(未进行购买下载可退充值款),文档一经付费(服务费)、不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
4、如你看到网页展示的文档有www.zixin.com.cn水印,是因预览和防盗链等技术需要对页面进行转换压缩成图而已,我们并不对上传的文档进行任何编辑或修改,文档下载后都不会有水印标识(原文档上传前个别存留的除外),下载后原文更清晰;试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓;PPT和DOC文档可被视为“模板”,允许上传人保留章节、目录结构的情况下删减部份的内容;PDF文档不管是原文档转换或图片扫描而得,本站不作要求视为允许,下载前自行私信或留言给上传者【可****】。
5、本文档所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用;网站提供的党政主题相关内容(国旗、国徽、党徽--等)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。
6、文档遇到问题,请及时私信或留言给本站上传会员【可****】,需本站解决可联系【 微信客服】、【 QQ客服】,若有其他问题请点击或扫码反馈【 服务填表】;文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“【 版权申诉】”(推荐),意见反馈和侵权处理邮箱:1219186828@qq.com;也可以拔打客服电话:4008-655-100;投诉/维权电话:4009-655-100。